paclitaxel

This page shows the latest paclitaxel news and features for those working in and with pharma, biotech and healthcare.

Chi-Med and Lilly’s cancer drug Elunate a milestone for China

Chi-Med has a pivotal phase 3 trial of fruquintinib as a second line combination with paclitaxel in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma due in the first

Latest news

AZ drug matched to cancer mutation passes phase 2 test

At this year’s ASCO meeting, the results of the phase 2 PAKT trial in triple negative breast cancer (TNBC) showed that adding the drug to first-line therapy with paclitaxel ... resulted in significant extensions in both progression-free survival (to
Roche gains speedy review for Tecentriq in first-line breast cancer

Tecentriq in combination with nab-paclitaxel has the potential to meaningfully advance treatment for people with PD-L1-positive, metastatic triple-negative breast cancer.
A look ahead to key trial readouts at ESMO

Roche’s Tecentriq (atezolizumab) will feature in the Impassion 130 trial as a first-line treatment for triple negative breast cancer (TNBC) as a combination with nab-paclitaxel, with a positive
Roche’s Tecentriq misses survival mark in frontline NSCLC

chemotherapy drugs carboplatin and paclitaxel – which could challenge Merck’s position – was delayed by the FDA for three months.
MSD wins key EU approval for Keytruda, Alimta combo

will take another three months for it to rule on Tecentriq in combination with Avastin, carboplatin and paclitaxel in the same frontline setting for metastatic non-squamous NSCLC patients.

More from news
Approximately 9 fully matching, plus 101 partially matching documents found.

Latest Intelligence

Pharma deals in May 2015

Sorrento (Igdrasol)/ NantPharma. Asset acquisition. Acquisition of Igdrasol including Cynviloq (paclitaxel nanoparticle).
The rise of chronic disease in BRIC markets

For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

BMS appoints oncology development head

Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Associate Director: £75, 000-90, 000

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Account Director: Competitive Salary Offered

Medical Writer: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Director, Medical Education: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Business Director: Competitive Salary Offered

Account Manager / Account Director: Competative

Account Director – Healthcare Marketing – Berks: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Director – Health Policy – Global Agency: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Director, Healthcare Marketing Agency: Salary TBC

Global Business Development Director – Health Education: excellent commission

Senior Account Manager: Competitive Salary Offered

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Senior Medical Writer: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up: As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?: Healthcare leaders in the European Union should begin preparing for a breakthrough now...